Skip to main content
SpringerLink
Log in

Pathologic, Clinical, and Epidemiologic Characteristics of Invasive Lobular Breast Carcinoma and a Review of Studies Evaluating its Association with Hormone Replacement Therapy

  • Chapter
Hormonal Carcinogenesis IV

  • 599 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Potter JD, Cerhan JR, Sellers TA, et al (1995) Progesterone and estrogen receptors and mammary neoplasia in the Iowa Women’s Health Study: how many types of breast cancer are there? Cancer Epidemiol Biomarker Prev 4:319–326.

    CAS  Google Scholar 

  2. Schnitt S, Connolly J, Recht A, et al (1989) Influence of infiltrating lobular histology on local tumor control in breast cancer patients treated with conservative surgery and radiotherapy. Cancer 64:448–454.

    Article  PubMed  CAS  Google Scholar 

  3. Sastre-Garau X, Jouve M, Asselain B, et al (1996) Infiltrating lobular carcinoma of the breast. Clinicopathologic analysis of 975 cases with reference to data on conservative therapy and metastatic patterns. Cancer 77:113–120.

    Article  PubMed  CAS  Google Scholar 

  4. Davis RP, Nora PF, Kooy RG, et al (1979) Experience with lobular carcinoma of the breast: Emphasis on recent aspects of management. Arch Surg 114:485.

    PubMed  CAS  Google Scholar 

  5. Acs G, Lawton TJ, Rebbeck TR, et al (2001) Differential expression of ecadherin in lobular and ductal neoplasms of the breast and its biologic and diagnostic implications. Am J Clin Pathol 115:85–98.

    Article  PubMed  CAS  Google Scholar 

  6. Stierer M, Rosen H, Weber R, et al (1993) Immunohistochemical and biochemical measurement of estrogen and progesterone receptors in primary breast cancer: Correlation of histopathology and prognostic factors. Ann Surg 218:13–21.

    PubMed  CAS  Google Scholar 

  7. Oyama T, Kashiwabara K, Yoshimoto K, et al (1998) Frequent overexpression of the cyclin D1 oncogene in invasive lobular carcinoma of the breast. Cancer Res 58:2876–2880.

    PubMed  CAS  Google Scholar 

  8. Domagala W, Markiewski M, Kubiak R, et al (1993) Immunohistochemical profile of invasive lobular carcinoma of the breast: predominantly vimentin and p53 protein negative, cathepsin D and oestrogen receptor positive. Virchow Archiv 423:497–502.

    Article  CAS  Google Scholar 

  9. Coradini D, Pellizzaro C, Veneroni S, et al (2002) Infiltrating ductal and lobular breast carcinomas are characterized by different interrelationships among markers related to angiogenesis and hormone dependence. Brit J Cancer 87:1105–1111.

    Article  PubMed  CAS  Google Scholar 

  10. Lee AHS, Dublin EA, Bobrow LG, et al (1998) Invasive lobular and invasive ductal carcinoma of the breast show distinct patterns of vascular endothelial growth factor expression and angiogenesis. J Pathol 185:394–401.

    Article  PubMed  CAS  Google Scholar 

  11. Nishizaki T, Chew K, Chu L, et al (1997) Genetic alterations in lobular breast cancer by comparative genomic hybridization. Int J Cancer 74:513–517.

    Article  PubMed  CAS  Google Scholar 

  12. Gunther K, Merkelbach-Bruse S, Amo-Takyi BK, et al (2001) Differences in genetic alterations between primary lobular and ductal breast cancers detected by comparative genomic hybridization. J Pathol 193:40–47.

    Article  PubMed  CAS  Google Scholar 

  13. Dixon J, Anderson T, Page D, et al (1982) Infiltrating lobular carcinoma of the breast. Histopathology 6:149–161.

    PubMed  CAS  Google Scholar 

  14. Yeatman TJ, Cantor AB, Smith TJ, et al (1995) Tumor biology of infiltrating lobular carcinoma. Implications for management. Ann Surg 222:549–559.

    PubMed  CAS  Google Scholar 

  15. Silverstein MJ, Lewinsky BS, Waisman JR, et al (1994) Infiltrating lobular carcinoma: is it different from infiltrating duct carcinoma? Cancer 74:1673–1677.

    Article  Google Scholar 

  16. Krecke K, Gisvold J (1993) Invasive lobular carcinoma of the breast: Mamographic findings and extent of disease at diagnosis in 184 patients. Am J Roentgenol 161:957–960.

    CAS  Google Scholar 

  17. Du Toit RS, Locker AP, Ellis IO, et al (1991) An evaluation of differences in prognosis, recurrence patterns and receptor status between invasive lobular and other invasive carcinomas of the breast. Eur J Surg Oncology 17:251–257.

    Google Scholar 

  18. Li CI, Moe RE, Daling JR (2003) Risk of mortality by histologic type of breast cancer among women aged 50 to 79 years. Arch Int Med 163:2149–2153.

    Article  Google Scholar 

  19. Li CI, Malone KE, Daling JR (2002) Differences in breast cancer hormone receptor status and histology by race and ethnicity among women 50 years of age and older. Cancer Epidemiol Biomarker Prev 11:601–607.

    Google Scholar 

  20. Friedman-Koss D, Crespo CJ, Bellantoni MF, et al (2002) The relationship of race/ethnicity and social class to hormone replacement therapy: results from the Third National Health and Nutrition Examination Survey 1988–1994. Menopause 9:264–272.

    Article  PubMed  Google Scholar 

  21. Li CI, Anderson BO, Porter P, et al (2000) Changing incidence rate of invasive lobular breast carcinoma among older women. Cancer 88:2561–2569.

    Article  PubMed  CAS  Google Scholar 

  22. Li CI, Anderson BO, Daling JR, et al (2003) Trends in incidence rates of invasive lobular and ductal breast carcinoma. JAMA 289:1421–1424.

    Article  PubMed  Google Scholar 

  23. Verkooijen HM, Fioretta G, Vlastos G, et al (2003) Important increase of invasive lobular breast cancer incidence in Geneva, Switzerland. Int J Cancer 104:778–781.

    Article  PubMed  CAS  Google Scholar 

  24. Wysowski DK, Golden L, Burke L (1995) Use of menopausal estrogens and medroxyprogesterone in the United States, 1982–1992. Obstet Gynecol 85:6–10.

    Article  PubMed  CAS  Google Scholar 

  25. Daling JR, Malone KE, Doody DR, et al (2002) Relation of regimens of combined hormone replacement therapy to lobular, ductal, and other histologic types of breast carcinoma. Cancer 95:2455–2464.

    Article  PubMed  CAS  Google Scholar 

  26. Collaborative Group on Hormonal Factors in Breast Cancer (1997) Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 350:1047–1059.

    Article  Google Scholar 

  27. Writing Group for the Women’s Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288:321–333.

    Article  Google Scholar 

  28. Li CI, Weiss NS, Stanford JL, et al (2000) Hormone replacement therapy in relation to risk of lobular and ductal breast carcinoma in middle-aged women. Cancer 88:2570–2577.

    Article  PubMed  CAS  Google Scholar 

  29. Chen CL, Weiss NS, Newcomb P, et al (2002) Hormone replacement therapy in relation to breast cancer. JAMA 287:734–741.

    Article  PubMed  CAS  Google Scholar 

  30. Newcomb PA, Titus-Ernstoff L, Egan KM, et al (2002) Postmenopausal estrogen and progestin use in relation to breast cancer risk. Cancer Epidemiol Biomarker Prev 11:593–600.

    CAS  Google Scholar 

  31. Newcomer LM, Newcomb PA, Potter JD, et al (2003) Postmenopausal hormone therapy and risk of breast cancer by histologic type (United States). Cancer Causes Control 14:225–233.

    Article  PubMed  Google Scholar 

  32. Li CI, Malone KE, Porter PL, et al (2003) Relationship between long-term use of hormone replacement therapy and risk of breast cancer among women 65–79 years of age. JAMA 289:3254–3263.

    Article  PubMed  CAS  Google Scholar 

  33. Colditz GA, Hankinson SE, Hunter DJ, et al (1995) The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. New Engl J Med 332:1589–1593.

    Article  PubMed  CAS  Google Scholar 

  34. Ross RK, Paganini-Hill A, Wan PC, et al (2000) Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 92:328–332.

    Article  PubMed  CAS  Google Scholar 

  35. Steinberg KK, Smith SJ, Thacker SB, et al (1994) Breast cancer risk and duration of estrogen use: the role of study design in meta-analysis. Epidemiology 5:415–421.

    Article  PubMed  CAS  Google Scholar 

  36. Colditz GA, Stampfer MJ, Willett WC, et al (1990) Prospective study of estrogen replacement therapy and risk of breast cancer in postmenopausal women. JAMA 264:2648–2653.

    Article  PubMed  CAS  Google Scholar 

  37. Colditz GA, Stampfer MJ, Willett WC, et al (1992) Type of postmenopausal hormone use and risk of breast cancer: 12-year follow-up from the Nurses’ Health Study. Cancer Causes Control 3:433–439.

    Article  PubMed  CAS  Google Scholar 

  38. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence-SEER 9 Regs, Nov 2002 Sub (1973–2000), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2003, based on the November 2002 submission.

    Google Scholar 

  39. Shi YE, Liu YE, Lippman ME, et al (1994) Progestins and antiprogestins in mammary tumor growth and metastasis. Human Reproduction 9:162–173.

    PubMed  Google Scholar 

  40. Graham JD, Clarke CL (1997) Physiological action of progesterone in target tissue. Endocrine Rev 18:502–519.

    Article  CAS  Google Scholar 

  41. Meyer JS (1977) Cell proliferation in normal human breast ducts, fibroadenomas, and other ductal hyperplasias measured by nuclear labeling with tritiated thymidine. Hum Pathol 8:67–81.

    PubMed  CAS  Google Scholar 

  42. Masters JRW, Drife JO, Scarisbrick JJ (1977) Cyclic variation of DNA synthesis in human breast epithelium. J Natl Cancer Inst 58:1263–1265.

    PubMed  CAS  Google Scholar 

  43. Ferguson DJP, Anderson TJ (1981) Morphological evaluation of cell turnover in relation to the menstrual cycle in the “resting” human breast. Br J Cancer 44:177–181.

    PubMed  CAS  Google Scholar 

  44. Anderson TJ, Ferguson DJP, Raab GM (1982) Cell turnover in the “resting” human breast: influence of parity, contraceptive pill, age, and laterality. Br J Cancer 46:376–382.

    PubMed  CAS  Google Scholar 

  45. Haslam SZ (1988) Progesterone effects on deoxyribonucleic acid synthesis in normal mouse mammary glands. Endocrinology 122:464–470.

    Article  PubMed  CAS  Google Scholar 

  46. Lydon JP, DeMayo FJ, Funk CR, et al (1995) Mice lacking progesterone receptor exhibit pleiotropic reproductive abnormalities. Genes Dev 9:2266–2278.

    PubMed  CAS  Google Scholar 

  47. Musgrove EA, Lee CS, Sutherland RL (1991) Progestins both stimulate and inhibit breast cancer cell cycle progression while increasing expression of transforming growth factor α, epidermal growth factor receptor, c-fos, and c-myc genes. Mol Cell Biol 11:5032–5043.

    PubMed  CAS  Google Scholar 

  48. Musgrove WA, Hamilton JA, Lee CS, et al (1991) Growth factor, steroid, and steroid antagonist regulation of cyclin gene expression associated with changes in T-47D human breast cancer cell cycle progression. Mol Cell Biol 13:3577–3587.

    Google Scholar 

  49. Murphy LC, Murphy LJ, Dubik D, et al (1988) Epidermal growth factor gene expression in human breast cancer cells: regulation of expression by progestins. Cancer Res 46:4555–4560.

    Google Scholar 

  50. Murphy LJ, Sutherland RL, Stead B, et al (1986) Progestin regulation of epidermal growth factor receptor in human mammary carcinoma cells. Cancer Res 46:728–734.

    PubMed  CAS  Google Scholar 

  51. Murphy LC, Murphy LK, Shiu RPC (1988) Progestin regulation of EGF-receptor mRNA accumulation in T-47D human breast cancer cells. Biochem Biophys Res Commun 150:192–196.

    Article  PubMed  CAS  Google Scholar 

  52. Murphy LC, Dotzlaw H (1989) Regulation of transforming growth factor α and transforming growth factor β messenger ribonucleic acid abundance in T-47D human breast cancer cells. Mol Endocrinol 3:611–617.

    Article  PubMed  CAS  Google Scholar 

  53. Lange C, Richer JK, Horwitz KB (1999) Hypothesis: progesterone primes breast cancer cells for cross-talk with proliferative or antiproliferative signals. Molec Endocrinol 13:829–836.

    Article  CAS  Google Scholar 

  54. Kastner P, Krust A, Turcotte B, et al (1990) Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. EMBO J 9:1603–1614.

    PubMed  CAS  Google Scholar 

  55. Shyamala G, Yang X, Silberstein G, et al (1998) Transgenic mice carrying an imbalance in the native ratio of A to B forms of progesterone receptor exhibit developmental abnormalities in mammary gland. Proc Nat Acad Sci USA 95:696–701.

    Article  PubMed  CAS  Google Scholar 

  56. Shyamala G, Yang X, Cardiff RD, et al (2000) Impact of progesterone receptor on cell-fate decisions during mammary gland development. Proc Nat Acad Sci USA 97:3044–3049.

    Article  PubMed  CAS  Google Scholar 

  57. Richer JK, Jacobsen BM, Manning NG, et al (2002) Differential gene regulation by the two progesterone receptor isoforms in human breast cancer cells. J Biol Chem 277:5209–5218.

    Article  PubMed  CAS  Google Scholar 

  58. Ariga N, Suzuki T, Moriya T, et al (2001) Progesterone receptor A and B isoforms in the human breast and its disorders. Jpn J Cancer Res 92:302–308.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Fred Hutchinson Cancer Research Center, Seattle, WA, USA

    Christopher I. Li

Authors
  1. Christopher I. Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Etiology and Prevention of Hormonal Cancers, The University of Kansas Medical Center, 3901 Rainbow Boulevard, 2010 Breidenthal, Kansas City, KS, 66160-7417

    Jonathan J. Li (Profesor of Pharmacology, Toxicology and Therapeutics and Director) & Sara A. Li (Associate Research Professor of Pharmacology, Toxicology and Therapeutics) (Profesor of Pharmacology, Toxicology and Therapeutics and Director) &  (Associate Research Professor of Pharmacology, Toxicology and Therapeutics)

  2. Departmento de Patologia, Facultad de Medicina y Odontologia, Camino de Vera s/n, Valencia, 46071, Spain

    Antonio Llombart-Bosch (Director) (Director)

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Springer Science+Business Media, Inc.

About this chapter

Cite this chapter

Li, C.I. (2005). Pathologic, Clinical, and Epidemiologic Characteristics of Invasive Lobular Breast Carcinoma and a Review of Studies Evaluating its Association with Hormone Replacement Therapy. In: Li, J.J., Li, S.A., Llombart-Bosch, A. (eds) Hormonal Carcinogenesis IV. Springer, Boston, MA. https://doi.org/10.1007/0-387-23761-5_4

Download citation

  • DOI: https://doi.org/10.1007/0-387-23761-5_4

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-0-387-23783-1

  • Online ISBN: 978-0-387-23761-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation